OXB - OXFORD BIOMEDICA - Share Chat

Oxford Biomedica is a leading UK-based gene and cell therapy company, specialising in the development and manufacturing of lentiviral vectors. Leveraging its proprietary LentiVector® platform, the company operates as a critical Contract Development and Manufacturing Organisation (CDMO) for advanced therapy medicinal products (ATMPs).

It supports a diverse range of biopharmaceutical clients, providing essential components and expertise for gene therapy development and commercial supply. Notable collaborations include the supply of lentiviral vectors for Novartis’s CAR-T therapy, Kymriah, and its significant role in manufacturing the Oxford/AstraZeneca COVID-19 vaccine. OXB is strategically positioned at the forefront of the rapidly expanding gene therapy market, pursuing both partnered programmes and its own therapeutic pipeline.